Genome-wide screen identifies PVT1 as a regulator of Gemcitabine sensitivity in human pancreatic cancer cells

Biochemical and Biophysical Research Communications

Volumn 407, Issue 1, 2011, Pages 1-6

  You, Lei ^a   Chang, De ^b   Du, Hong Zhen ^b   Zhao, Yu Pei ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

Gemcitabine; Genome wide screen; Pancreatic cancer; Piggybac transposon; PVT 1

Indexed keywords

COMPLEMENTARY DNA; GEMCITABINE; MYC PROTEIN; PVT1 PROTEIN; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; DNA INTEGRATION; DRUG SENSITIVITY; GENE AMPLIFICATION; GENE INSERTION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC ANALYSIS; GENETIC SCREENING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; INTRON; PANCREAS CANCER; PRIORITY JOURNAL; TRANSCRIPTION REGULATION; TRANSPOSON;

ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; CLONING, MOLECULAR; DEOXYCYTIDINE; DNA TRANSPOSABLE ELEMENTS; DRUG RESISTANCE, NEOPLASM; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MUTAGENESIS; PANCREATIC NEOPLASMS; PROTEINS;

EID: 79953161952     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.02.027     Document Type: Article

References (35)

1. Jemal A., Siegel R., Xu J., et al. Cancer Statistics 2010. CA Cancer J. Clin. 2010, 60:277-300.
2. Von Wichert G., Seufferlein T., Adler G. Palliative treatment of pancreatic cancer. J. Dig. Dis. 2008, 9:1-7.
3. O'Reilly E.M., Abou-Alfa G.K. Cytotoxic therapy for advanced pancreatic adenocarcinoma. Semin. Oncol. 2007, 34:347-353.
4. Xiong H.Q., Carr K., Abbruzzese J.L. Cytotoxic chemotherapy for pancreatic cancer: advances to date and future directions. Drugs 2006, 66:1059-1072.
5. Burris H., Rocha-Lima C. New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways. Oncologist 2008, 13:289-298.
6. Kleespies A., Jauch K.W., Bruns C.J. Tyrosine kinase inhibitors and gemcitabine: new treatment options in pancreatic cancer?. Drug Resist. Update 2006, 9:1-18.
7. Danovi S.A., Wong H.H., Lemoine N.R. Targeted therapies for pancreatic cancer. Br. Med. Bull. 2008, 87:97-130.
8. Ko A.H. Future strategies for targeted therapies and tailored patient management in pancreatic cancer. Semin. Oncol. 2007, 34:354-364.
9. Tanase C.P., Neagu M., Albulescu R., et al. Advances in pancreatic cancer detection. Adv. Clin. Chem. 2010, 51:145-180.
10. Bozic I., Antal T., Ohtsuki H., et al. Accumulation of driver and passenger mutations during tumor progression. Proc. Natl. Acad. Sci. USA 2010, 107:18545-18550.
11. Jones S., Zhang X., Parsons D.W., et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321:1801-1806.
12. Habiro A., Tanno S., Koizumi K., et al. Involvement of p38 mitogen-activated protein kinase in gemcitabine-induced apoptosis in human pancreatic cancer cells. Biochem. Biophys. Res. Commun. 2004, 316:71-77.
13. Koizumi K., Tanno S., Nakano Y., et al. Activation of p38 mitogen-activated protein kinase is necessary for gemcitabine-induced cytotoxicity in human pancreatic cancer cells. Anticancer Res. 2005, 25:3347-3353.
14. Azorsa D.O., Gonzales I.M., Basu G.D., et al. Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer. J. Transl. Med. 2009, 7:43-54.
15. Li L., Cohen S.N. Tsg101: a novel tumor susceptibility gene isolated by controlled homozygous functional knockout of allelic loci in mammalian cells. Cell 1996, 85:319-329.
16. Zhang Y.W., Liu L., Zhang S.X., et al. A functional mouse retroposed gene rps 23r1 reduces Alzheimer's β-Amyloid levels and Tau phosphorylation. Neuron 2009, 64:328-340.
17. Dupuy A.J., Akagi K., Largaespada D.A., et al. Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system. Nature 2005, 436:221-226.
18. Starr T.K., Allaei R., Silverstein K.A., et al. A transposon-based genetic screen in mice identifies genes altered in colorectal cancer. Science 2009, 323:1747-1750.
19. Kool J., Berns A. High-throughput insertional mutagenesis screens in mice to identify oncogenic networks. Nat. Rev. Cancer 2009, 9:389-399.
20. Wang W., Bradley A., Huang Y. A piggyBac transposon-based genome-wide library of insertionally mutated Blm-deficient murine ES cells. Genome Res. 2009, 19:667-673.
21. Rad R., Rad L., Wang W., et al. piggyBac transposon mutagenesis: a tool for cancer gene discovery in mice. Science 2010, 329:413-417.
22. Gossen M., Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl Acad. Sci. USA 1992, 89:5547-5551.
23. Bronstein I., Fortin J., Stanley P.E., et al. Chemiluminescent and bioluminescent reporter gene assays. Anal. Biochem. 1994, 219:169-181.
24. Uren A.G., Mikkers H., Kool J., et al. A high-throughput splinkerette-PCR method for the isolation and sequencing of retroviral insertion sites. Nat. Protoc. 2009, 4:789-798.
25. O'Connor M.J., Martin N.M., Smith G.C. Targeted cancer therapies based on the inhibition of DNA strand break repair. Oncogene 2007, 26:7816-7824.
26. Shtivelman E., Bishop J.M. The PVT gene frequently amplifies with MYC in tumor cells. Mol. Cell. Biol. 1989, 9:1148-1154.
27. Pleasance E.D., Stephens P.J., O'Meara S., et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 2010, 463:184-190.
28. Pomerantz M.M., Beckwith C.A., Regan M.M. Evaluation of the 8q24 prostate cancer risk locus and MYC expression. Cancer Res. 2009, 69:5568-5574.
29. Enciso-Mora V., Broderick P., Ma Y., et al. A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3). Nat. Genet. 2010, 42:1126-1130.
30. Shao R.G., Cao C.X., Shimizu T., et al. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. Cancer Res. 1997, 57:4029-4035.
31. Borg A., Baldetorp B., Ferno M., et al. C-myc amplification is an independent prognostic factor in postmenopausal breast cancer. Int. J. Cancer 1992, 51:687-691.
32. Palumbo A.P., Boccadoro M., Battaglio S., et al. Human homologue of Moloney leukemia virus integration-4 locus (MLVI-4), located 20 kilobases 3′of the myc gene is rearranged in multiple myelomas. Cancer Res. 1990, 50:6478-6482.
33. Marcu K.B., Bossone S.A., Patel A.J. Myc function and regulation. Annu. Rev. Biochem. 1992, 61:809-860.
34. Shtivelman E., Bishop J.M. Effects of translocations on transcription from PVT. Mol. Cell. Biol. 1990, 10:1835-1839.
35. Huppi K., Volfovsky N., Wahlberg B., et al. The identification of microRNAs in a genomically unstable region of human chromosome 8q24. Mol. Cancer Res. 2008, 6:212-221.